ATE348164T1 - Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie - Google Patents
Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilieInfo
- Publication number
- ATE348164T1 ATE348164T1 AT00935043T AT00935043T ATE348164T1 AT E348164 T1 ATE348164 T1 AT E348164T1 AT 00935043 T AT00935043 T AT 00935043T AT 00935043 T AT00935043 T AT 00935043T AT E348164 T1 ATE348164 T1 AT E348164T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- nucleic acids
- tgf
- vector
- gdf
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 3
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 230000000508 neurotrophic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Eye Examination Apparatus (AREA)
- Developing Agents For Electrophotography (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109714 | 1999-05-17 | ||
| EP99114853 | 1999-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE348164T1 true ATE348164T1 (de) | 2007-01-15 |
Family
ID=26153004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00935043T ATE348164T1 (de) | 1999-05-17 | 2000-05-16 | Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060148709A1 (de) |
| EP (1) | EP1179067B1 (de) |
| JP (1) | JP2002543841A (de) |
| AT (1) | ATE348164T1 (de) |
| AU (1) | AU5067100A (de) |
| CA (1) | CA2372119A1 (de) |
| CY (1) | CY1105910T1 (de) |
| DE (1) | DE60032355T2 (de) |
| DK (1) | DK1179067T3 (de) |
| ES (1) | ES2275513T3 (de) |
| PT (1) | PT1179067E (de) |
| WO (1) | WO2000070051A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2300325T3 (es) * | 2000-04-20 | 2008-06-16 | St Vincent's Hospital Sydney Limited | Ensayo diagnostico que implica la citoquina 1 inhibitoria de macrofagos (mc1). |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| EP2047275B1 (de) * | 2006-08-04 | 2011-06-01 | Medizinische Hochschule Hannover | Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis |
| EP1884777A1 (de) * | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Mittel und Verfahren zur Risikobewertung von Herzeingriffen auf GDF-15-Basis |
| CN100588717C (zh) * | 2007-03-21 | 2010-02-10 | 中国医学科学院阜外心血管病医院 | 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途 |
| ES2457529T3 (es) | 2007-10-10 | 2014-04-28 | F. Hoffmann-La Roche Ag | Medios y métodos para controlar el infarto de miocardio y su tratamiento |
| EP2103943A1 (de) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern |
| CN102203619B (zh) | 2008-10-31 | 2015-12-16 | 圣文森特医院悉尼有限公司 | 慢性肾病中的预测方法 |
| KR20100054711A (ko) * | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
| EP2211182A1 (de) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Verfahren zur Bewertung des Schweregrades einer Leberzirrhose |
| EP2209003A1 (de) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Mittel und Verfahren zur Differenzierung zwischen Fibrose und Zirrhose |
| CN102498403B (zh) | 2009-09-17 | 2015-09-16 | 霍夫曼-拉罗奇有限公司 | 左心室肥大的多标记组 |
| ES2647461T3 (es) | 2009-12-18 | 2017-12-21 | F. Hoffmann-La Roche Ag | GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca |
| JP5224308B2 (ja) * | 2010-02-22 | 2013-07-03 | 公立大学法人横浜市立大学 | 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用 |
| EP2388594A1 (de) | 2010-05-17 | 2011-11-23 | Roche Diagnostics GmbH | Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung |
| WO2012020045A1 (en) | 2010-08-10 | 2012-02-16 | Roche Diagnostics Gmbh | Method for selecting patients with stable coronary artery disease for pci or medical treatment |
| ES2534921T3 (es) | 2010-08-26 | 2015-04-30 | F. Hoffmann-La Roche Ag | Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca |
| EP2439535A1 (de) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2 |
| WO2012066140A1 (en) | 2010-11-19 | 2012-05-24 | Roche Diagnostics Gmbh | Method for monitoring physical training in healthy and diseased individuals |
| EP2490027A1 (de) | 2011-02-15 | 2012-08-22 | Roche Diagnostics GmbH | Mittel und Verfahren zur Diagnose von Schwangerschaftskomplikationen auf Grundlage von GDF-15 und PlGF/sFlt1 |
| WO2012146645A1 (en) | 2011-04-27 | 2012-11-01 | Roche Diagnostics Gmbh | Diagnosis of kidney injury after surgery |
| EP2574932A1 (de) | 2011-09-30 | 2013-04-03 | Roche Diagnostics GmbH | sFlt1 in Patienten während oder unmittelbar nach körperlicher Betätigung |
| EP2581040A1 (de) | 2011-10-10 | 2013-04-17 | Roche Diagnostics GmbH | TNT-basiertes Herzhypertrophierisiko im Zusammenhang mit physiologischem Training und Führung in Athleten |
| EP3088900B1 (de) | 2011-10-17 | 2020-08-12 | Roche Diagniostics GmbH | Troponin als marker für intermittierendes vorhofflimmern |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| EP2597467A1 (de) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Mittel und Verfahren zur proSP-B-basierten Diagnose von Lungenstauung bei Patienten mit akutem Koronarsyndrom |
| CN104853775B (zh) | 2012-09-26 | 2023-10-20 | 尤利乌斯·马克西米利安维尔茨堡大学 | 针对生长和分化因子15(gdf-15)的单克隆抗体 |
| CN113759128A (zh) | 2012-12-04 | 2021-12-07 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
| MX370720B (es) | 2012-12-21 | 2019-12-20 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15. |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| EP3441768A3 (de) | 2013-08-26 | 2019-03-20 | Roche Diagnostics GmbH | Marker zur statinbehandlungsstratifikation bei herzversagen |
| CA2929444C (en) | 2013-11-04 | 2023-12-19 | F. Hoffmann-La Roche Ag | Biomarkers and methods for progression prediction for chronic kidney disease |
| EP2899544B1 (de) | 2014-01-28 | 2018-12-26 | Roche Diagnostics GmbH | Biomarker zur Risikobewertung und Behandlungsüberwachung bei Patienten mit Herzinsuffizienz, die auf Basis des natriuretischen Peptids des Typs B behandelt werden |
| BR122023027559A2 (pt) | 2014-03-26 | 2024-01-30 | Julius-Maximilians-Universität Würzburg | Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos |
| EP3413052B1 (de) | 2014-03-26 | 2022-12-28 | Roche Diagnostics GmbH | Igfbp7 zur diagnose von diastolischer dysfunktion |
| UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| JP6803833B2 (ja) | 2014-10-29 | 2020-12-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 死亡率のリスク予測のためのバイオマーカー |
| MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
| CA3000290C (en) | 2015-10-02 | 2023-02-21 | Julius-Maximilians-Universitat Wurzburg | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| HRP20221530T1 (hr) * | 2015-10-02 | 2023-03-17 | Julius-Maximilians-Universität Würzburg | Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke |
| JP6859334B2 (ja) | 2015-10-08 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７ |
| CN105603093A (zh) * | 2016-02-05 | 2016-05-25 | 广州复能基因有限公司 | 以MIC-1 cDNA为模板制备RNA探针的方法 |
| CN117986363A (zh) | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| JP2021014434A (ja) * | 2019-07-12 | 2021-02-12 | 国立大学法人千葉大学 | うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β１ |
| EP3943946A1 (de) | 2020-07-20 | 2022-01-26 | F. Hoffmann-La Roche AG | Gdf-15 zur vorhersage der erkrankungsschwere eines patienten mit covid-19 |
| IL302646A (en) | 2020-11-10 | 2023-07-01 | Catalym Gmbh | Anti-GDF15 antibody and dosage regimen for cancer treatment |
| US20240230673A1 (en) | 2021-04-30 | 2024-07-11 | Roche Diagnostics Operations, Inc. | Gdf15 marker panels for early detection of sepsis |
| CN117321419A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的Presepsin标志物组 |
| JP2024537774A (ja) | 2021-09-29 | 2024-10-16 | エフ． ホフマン－ラ ロシュ アーゲー | 敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル |
| CN118742814A (zh) | 2022-02-21 | 2024-10-01 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的dll1标志物组 |
| WO2023175152A1 (en) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
| CN118922721A (zh) | 2022-03-18 | 2024-11-08 | 豪夫迈·罗氏有限公司 | 用于2型与1型急性心肌梗死的早期辨别的cMyBPC标志物组合 |
| CN114891086B (zh) * | 2022-06-01 | 2024-03-26 | 恺佧生物科技(上海)有限公司 | 一种生物素标记的gdf15的复性方法 |
| WO2024160752A1 (en) | 2023-01-30 | 2024-08-08 | F. Hoffmann-La Roche Ag | Effect induced by a sodium-glucose cotransporter inhibitor (SGLTi) in a subject suffering from a cardiovascular disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180602B1 (en) * | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| US5994102A (en) * | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| DE69637844D1 (de) * | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
| US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US6524802B1 (en) * | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| NZ334592A (en) * | 1996-09-11 | 2000-10-27 | Ortho Mcneil Pharm Inc | Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer |
| FR2761258B1 (fr) * | 1997-03-26 | 1999-06-11 | Rhone Poulenc Rorer Sa | Procede de stimulation de la regeneration nerveuse |
| DE69821629T2 (de) * | 1997-09-19 | 2005-01-13 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Kombinationen von Cytokinen mit neurotroper Aktivität |
| AU4679300A (en) * | 1999-04-26 | 2000-11-10 | Stem Cell Pharmaceuticals, Inc. | Tgf-alpha polypeptides, functional fragments and methods of use therefor |
-
2000
- 2000-05-16 WO PCT/EP2000/004445 patent/WO2000070051A1/en not_active Ceased
- 2000-05-16 DE DE60032355T patent/DE60032355T2/de not_active Expired - Fee Related
- 2000-05-16 PT PT00935043T patent/PT1179067E/pt unknown
- 2000-05-16 JP JP2000618457A patent/JP2002543841A/ja active Pending
- 2000-05-16 AU AU50671/00A patent/AU5067100A/en not_active Abandoned
- 2000-05-16 EP EP00935043A patent/EP1179067B1/de not_active Expired - Lifetime
- 2000-05-16 ES ES00935043T patent/ES2275513T3/es not_active Expired - Lifetime
- 2000-05-16 CA CA002372119A patent/CA2372119A1/en not_active Abandoned
- 2000-05-16 DK DK00935043T patent/DK1179067T3/da active
- 2000-05-16 AT AT00935043T patent/ATE348164T1/de not_active IP Right Cessation
-
2006
- 2006-03-09 US US11/372,281 patent/US20060148709A1/en not_active Abandoned
-
2007
- 2007-01-08 CY CY20071100023T patent/CY1105910T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2275513T3 (es) | 2007-06-16 |
| WO2000070051A1 (en) | 2000-11-23 |
| EP1179067B1 (de) | 2006-12-13 |
| AU5067100A (en) | 2000-12-05 |
| PT1179067E (pt) | 2007-01-31 |
| JP2002543841A (ja) | 2002-12-24 |
| CA2372119A1 (en) | 2000-11-23 |
| EP1179067A1 (de) | 2002-02-13 |
| DE60032355T2 (de) | 2007-04-26 |
| DK1179067T3 (da) | 2007-03-19 |
| DE60032355D1 (de) | 2007-01-25 |
| US20060148709A1 (en) | 2006-07-06 |
| CY1105910T1 (el) | 2011-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE348164T1 (de) | Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie | |
| ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
| DE69435038D1 (de) | Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie | |
| NO20011386L (no) | Nye fremgangsmåter for fremvisning av (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger | |
| EP1067182A3 (de) | Sekretorische- oder Membranproteine | |
| IL140287A0 (en) | Methods for rapidly identifying small organic ligands | |
| CA2232727A1 (en) | Novel variants of green fluorescent protein, gfp | |
| ATE180261T1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
| DE60140773D1 (de) | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) | |
| WO2002002627A3 (en) | Interferon-like protein zcyto21 | |
| ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
| DE69117949D1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
| BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
| DE69618614D1 (de) | NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG | |
| DE69432449D1 (de) | Verfahren zur Herstellung von hydrophoben Polypeptiden, Proteinen und Peptiden | |
| ES2079621T3 (es) | Procedimiento de identificacion o de titulacion de proteinas y aplicaciones. | |
| IL162568A0 (en) | fluorescent protein from aequorea coerulscens and uses thereof | |
| WO2002074956A3 (en) | Dopaminergic neuronal survival-promoting factors and uses thereof | |
| WO2004094651A3 (en) | Novel human polypeptides encoded by polynucleotides | |
| WO2001029220A3 (en) | Mage-a12 antigenic peptides and uses thereof | |
| EP1702985A3 (de) | Bevorzugte neurofilamentprotein Segmente und Methode zu ihrer Verwendung | |
| ATE187202T1 (de) | Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung | |
| WO2003042374A3 (de) | Isolierung von neuronen und stammzellen für nervenfasern aus einer probe | |
| WO2002012541A3 (en) | Novel motor proteins and methods for their use | |
| WO2001096593A3 (en) | Novel motor proteins and methods for their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1179067 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |